• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

日本结直肠癌症学会(JSCCR)2010 年结直肠癌治疗指南。

Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer.

机构信息

Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8605, Japan.

出版信息

Int J Clin Oncol. 2012 Feb;17(1):1-29. doi: 10.1007/s10147-011-0315-2. Epub 2011 Oct 15.

DOI:10.1007/s10147-011-0315-2
PMID:22002491
Abstract

Colorectal cancer is a major cause of death in Japan, where it accounts for the largest number of deaths from malignant neoplasms in women and the third largest number in men. Many new treatment methods have been developed over the last few decades. The Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer (JSCCR Guidelines 2010) have been prepared to show standard treatment strategies for colorectal cancer, to eliminate disparities among institutions in terms of treatment, to eliminate unnecessary treatment and insufficient treatment, and to deepen mutual understanding between health-care professionals and patients by making these Guidelines available to the general public. These Guidelines have been prepared by consensuses reached by the JSCCR Guideline Committee, based on a careful review of the evidence retrieved by literature searches and in view of the medical health insurance system and actual clinical practice settings in Japan. Therefore, these Guidelines can be used as a tool for treating colorectal cancer in actual clinical practice settings. More specifically, they can be used as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient. As a result of the discussions held by the Guideline Committee, controversial issues were selected as Clinical Questions, and recommendations were made. Each recommendation is accompanied by a classification of the evidence and a classification of recommendation categories based on the consensus reached by the Guideline Committee members. Here we present the English version of the JSCCR Guidelines 2010.

摘要

结直肠癌是日本的主要死亡原因之一,在女性中其恶性肿瘤死亡率最高,在男性中排名第三。过去几十年中开发了许多新的治疗方法。为了展示结直肠癌的标准治疗策略,消除机构之间在治疗方面的差异,消除不必要和不充分的治疗,并通过向公众提供这些指南来加深医疗保健专业人员和患者之间的相互理解,日本癌症协会制定了结直肠癌治疗指南(JSCCR 指南 2010)。这些指南是由 JSCCR 指南委员会根据共识制定的,该共识基于对文献检索中检索到的证据进行仔细审查,并考虑到日本的医疗保险制度和实际临床实践环境。因此,这些指南可以作为实际临床实践中治疗结直肠癌的工具。更具体地说,它们可以作为从患者那里获得知情同意并为每位患者选择治疗方法的指南。根据指南委员会的讨论,选择了有争议的问题作为临床问题,并提出了建议。每项建议都附有证据分类和基于指南委员会成员达成的共识的建议类别分类。这里我们提供了 2010 年日本癌症协会结直肠癌治疗指南的英文版本。

相似文献

1
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer.日本结直肠癌症学会(JSCCR)2010 年结直肠癌治疗指南。
Int J Clin Oncol. 2012 Feb;17(1):1-29. doi: 10.1007/s10147-011-0315-2. Epub 2011 Oct 15.
2
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer.日本结直肠癌学会(JSCCR)2019 年结直肠癌治疗指南。
Int J Clin Oncol. 2020 Jan;25(1):1-42. doi: 10.1007/s10147-019-01485-z. Epub 2019 Jun 15.
3
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer.日本结直肠癌学会(JSCCR)2016年结直肠癌治疗指南。
Int J Clin Oncol. 2018 Feb;23(1):1-34. doi: 10.1007/s10147-017-1101-6. Epub 2017 Mar 27.
4
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer.日本结直肠癌学会(JSCCR)2014年结直肠癌治疗指南。
Int J Clin Oncol. 2015 Apr;20(2):207-39. doi: 10.1007/s10147-015-0801-z. Epub 2015 Mar 18.
5
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2016 for the Clinical Practice of Hereditary Colorectal Cancer (Translated Version).日本结直肠癌学会(JSCCR)2016年遗传性结直肠癌临床实践指南(翻译版)
J Anus Rectum Colon. 2018 May 25;2(Suppl I):S1-S51. doi: 10.23922/jarc.2017-028. eCollection 2018.
6
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer.日本结直肠癌学会(JSCCR)2020年遗传性结直肠癌临床实践指南。
Int J Clin Oncol. 2021 Aug;26(8):1353-1419. doi: 10.1007/s10147-021-01881-4. Epub 2021 Jun 29.
7
Impact of revisions of the JSCCR guidelines on the treatment of T1 colorectal carcinomas in Japan.日本结直肠癌诊疗规范(JSCCR)修订对T1期结直肠癌治疗的影响。
Z Gastroenterol. 2015 Apr;53(4):291-301. doi: 10.1055/s-0034-1385764. Epub 2015 Apr 10.
8
[Essential and interpretation of Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer].[日本结直肠癌学会(JSCCR)2019年结直肠癌治疗指南的要点与解读]
Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Nov 25;22(11):1088-1094. doi: 10.3760/cma.j.issn.1671-0274.2019.11.016.
9
[Lower G. I./Colon and Rectum Cancer Japanese Society for Cancer of the Colon and Rectum(JSCCR)Guidelines 2019 for the Treatment of Colorectal Cancer-Major Revised Points].[日本结直肠癌学会(JSCCR)2019年结直肠癌治疗指南——主要修订要点]
Gan To Kagaku Ryoho. 2019 Nov;46(11):1700.
10
Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer.日本妇科肿瘤学会 2017 年子宫颈癌治疗指南。
Int J Clin Oncol. 2019 Jan;24(1):1-19. doi: 10.1007/s10147-018-1351-y. Epub 2018 Oct 5.

引用本文的文献

1
Tumor Budding as a Risk Factor for Lymph Node Metastasis and Local Recurrence in pT1 Colorectal Cancer: A Systematic Review and Meta-Analysis.肿瘤芽生作为pT1期结直肠癌淋巴结转移和局部复发的危险因素:一项系统评价和荟萃分析
Gastro Hep Adv. 2025 May 27;4(9):100713. doi: 10.1016/j.gastha.2025.100713. eCollection 2025.
2
Removal of the "dog-ear" during laparoscopic anterior resection with double stapling technique reduces the anastomotic leakage: a prospective cohort study.腹腔镜前切除术采用双吻合器技术时切除“狗耳”可减少吻合口漏:一项前瞻性队列研究
Tech Coloproctol. 2025 Jul 18;29(1):143. doi: 10.1007/s10151-025-03178-4.
3

本文引用的文献

1
A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining.一项评估西妥昔单抗单药治疗表皮生长因子受体免疫组化阴性的转移性结直肠癌患者的 II 期、多中心研究。
Invest New Drugs. 2011 Feb;29(1):167-74. doi: 10.1007/s10637-009-9341-6. Epub 2009 Oct 15.
2
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.在MOSAIC试验中,奥沙利铂、氟尿嘧啶和亚叶酸作为II期或III期结肠癌辅助治疗可提高总生存率。
J Clin Oncol. 2009 Jul 1;27(19):3109-16. doi: 10.1200/JCO.2008.20.6771. Epub 2009 May 18.
3
Risk Factors for and Oncologic Impact of Anastomotic Leakage After Sphincter-Preserving Proctectomy for Mid/Low Rectal Cancer: A Multi-institutional Cohort Study in Japan.
中低位直肠癌保肛直肠切除术后吻合口漏的危险因素及肿瘤学影响:日本多机构队列研究
Ann Surg Oncol. 2025 Jul 7. doi: 10.1245/s10434-025-17763-2.
4
Standardization of the surgical technique and reporting for radical right colectomy with central vascular ligation and complete mesocolic excision (RRoC-STAR): Delphi consensus.右半结肠根治性切除术伴中央血管结扎及完整结肠系膜切除术(RRoC-STAR)的手术技术标准化与报告:德尔菲共识
BJS Open. 2025 May 7;9(3). doi: 10.1093/bjsopen/zraf066.
5
The role of UGT1A1 polymorphism in the management of colorectal cancer.UGT1A1基因多态性在结直肠癌治疗中的作用。
Oncol Rev. 2025 May 13;19:1547904. doi: 10.3389/or.2025.1547904. eCollection 2025.
6
Is radix ligation of the inferior mesenteric artery effective in Japanese-Style D3 radical lymph node dissection for sigmoid colon and rectal cancer surgery?-a single-center retrospective analysis since 2002.在乙状结肠和直肠癌手术的日式D3根治性淋巴结清扫术中,肠系膜下动脉根部结扎是否有效?——一项自2002年起的单中心回顾性分析
J Gastrointest Oncol. 2025 Apr 30;16(2):591-598. doi: 10.21037/jgo-24-815. Epub 2025 Mar 17.
7
Prognostic factors and long-term outcomes with endoscopic submucosal dissection for colorectal tumors in patients aged 75 years or older.75岁及以上患者结直肠肿瘤内镜黏膜下剥离术的预后因素及长期结局
DEN Open. 2025 May 6;6(1):e70137. doi: 10.1002/deo2.70137. eCollection 2026 Apr.
8
Central vascular ligation and complete mesocolon excision D3 lymphadenectomy: Standardization of surgical technique.中央血管结扎与完整结肠系膜切除术D3淋巴结清扫术:手术技术标准化
World J Gastrointest Surg. 2025 Apr 27;17(4):103704. doi: 10.4240/wjgs.v17.i4.103704.
9
Identification of predictors for lymph node metastasis in T2 colorectal cancer: retrospective cohort study from a high-volume hospital.T2期结直肠癌淋巴结转移预测因素的识别:来自一家大型医院的回顾性队列研究
BMC Cancer. 2025 Apr 15;25(1):700. doi: 10.1186/s12885-025-14104-0.
10
Early Rectal Cancer: Advances in Diagnosis and Management Strategies.早期直肠癌:诊断与管理策略的进展
Cancers (Basel). 2025 Feb 9;17(4):588. doi: 10.3390/cancers17040588.
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
西妥昔单抗与化疗联合作为转移性结直肠癌的初始治疗方案
N Engl J Med. 2009 Apr 2;360(14):1408-17. doi: 10.1056/NEJMoa0805019.
4
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.氟尿嘧啶、亚叶酸钙以及奥沙利铂联合或不联合西妥昔单抗用于转移性结直肠癌的一线治疗。
J Clin Oncol. 2009 Feb 10;27(5):663-71. doi: 10.1200/JCO.2008.20.8397. Epub 2008 Dec 29.
5
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.K-ras突变与晚期结直肠癌患者从西妥昔单抗治疗中获益的关系
N Engl J Med. 2008 Oct 23;359(17):1757-65. doi: 10.1056/NEJMoa0804385.
6
Colorectal endoscopic submucosal dissection: present status and future perspective, including its differentiation from endoscopic mucosal resection.结直肠内镜下黏膜下剥离术:现状与未来展望,包括其与内镜下黏膜切除术的区别
J Gastroenterol. 2008;43(9):641-51. doi: 10.1007/s00535-008-2223-4. Epub 2008 Sep 20.
7
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.卡培他滨联合奥沙利铂(XELOX方案)与5-氟尿嘧啶/亚叶酸钙联合奥沙利铂(FOLFOX-4方案)作为转移性结直肠癌二线治疗的随机III期非劣效性研究
Ann Oncol. 2008 Oct;19(10):1720-6. doi: 10.1093/annonc/mdn370. Epub 2008 Jun 10.
8
Colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up.结肠癌:欧洲肿瘤内科学会关于诊断、辅助治疗及随访的临床建议
Ann Oncol. 2008 May;19 Suppl 2:ii29-30. doi: 10.1093/annonc/mdn077.
9
KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.结直肠癌肿瘤中的KRAS突变特征与西妥昔单抗反应特征显著重叠。
J Clin Oncol. 2008 May 1;26(13):2228-30; author reply 2230-1. doi: 10.1200/JCO.2007.15.9186.
10
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.贝伐单抗联合奥沙利铂为基础的化疗作为转移性结直肠癌的一线治疗:一项随机III期研究。
J Clin Oncol. 2008 Apr 20;26(12):2013-9. doi: 10.1200/JCO.2007.14.9930.